Table 2 FasL expression in carcinoma cancers

Colorectal

19% in adenomas, 40% of stage I-II, 67% of stage III and 70% of stage IV of carcinoma

[46]

40.9% in adenoma versus 80.8% in carcinoma

[47]

Higher incidence of metastases and poorer patients' survival associate with FasL positive carcinomas

[48]

0 positive in normal epithelial cells, 2/7 positive in primary tumors, 4/4 positive in hepatic metastatic tumors

[49]

Adrenocortical

37.7% in adenomas versus 100% in the carcinoma

[50]

Bladder transitional cell

1) 0% in normal urothelium, 0% in G1, 14% in G2, and 75% in G3.

2) 13% in superficial Ta-T1 versus 81% in invasive T2-T4

[51]

0% in normal urothelium, 19% in T1, 21% in T2 and 49% in T3

[52]

Pancreatic ductal

1) 82% in primary versus 100% in hepatic metastases

2) Shorter survival for patients associates with FasL positive tumors

[53]

Nasopharyngeal

1) 0% in stage I, 57% in stage II, 58% in stage III and 82% in stage IV;

2) A lower rate of disease-free and overall survival for patients associates with positive FasL expression.

[54]

Gastric

36.2% in adenomas, 68.8% in early carcinoma, and 70.4% in advanced carcinoma

[55]

Cervical

1) 5/14 in inner 2/3 stromal invasion versus 10/10 outer 2/3 stromal invasion;

2) 7/15 without LN metastasis versus 8/9 with LN metastasis;

3) Reduced survival times in patients with FasL-expressing tumors

[56]

Esophageal

1) Higher incidence of LN metastasis associates with the tumors containing >25% FasL expression;

2) All cancer metastases in LN express FasL in >50% of the cells

[57]